Phase IIa study of tosposertib, a dual TGFβRI and VEGFR2 inhibitor, in combination with pembrolizumab in recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC).

Keytruda (pembrolizumab) - Merck (MSD)

tosposertib (NCE 401) - Tium Bio, Chiesi

https://www.asco.org/abstracts-presentations/257875

Hye Ryun Kim; Hun-taek Kim; Marya Chaney; Bhumsuk Keam; Sung-Bae Kim; Chang Gon Kim; Min Hee Hong; Jin Won Kim; Jin Hyoung Kang; Hojung An; Ji Hyun Park

Apr 21, 2026